Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of GSK2586881 in pulmonary arterial hypertension
2017-000212-41Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alunacedase alfa in pulmonary arterial hypertension (PAH), sponsored by GSK. Primary endpoints: Change from baseline in pulmonary vascular resistance (PVR), Change from baseline in cardiac output (CO) and 1 more. Started Jun 2017; status: completed.
02
Drugs
alunacedase alfa
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2017-000212-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000212-41.